Patients with ALL | Patients with OSC | Total | |
---|---|---|---|
Number of patients | 622 | 39 | 661 |
Gender n (%) | |||
Male | 372 (60) | 27 (69) | 399 (60) |
Female | 250 (40) | 12 (31) | 262 (40) |
Age at diagnosis (%) | |||
< 1 yr. n | 7 (1) | 0 | 7 (1) |
1–10 yr. n | 505 (81) | 9 (23) | 515 (78) |
> 10 yr. n | 109 (18) | 30 (77) | 138 (21) |
Mean ± SD yr | 6.39 (±4.3) | 13.1 (±3.5) | 6.6 (±4.3) |
Median (range) yr | 5.2 (0–18) | 13.2 (5–18) | 5.3 (0–18) |
Risk group n (%) | |||
SR | 165 (27) | 3 (7) | 168 (25) |
IR | 355 (57) | 24 (62) | 379 (58) |
HR | 100 (16) | 12 (31) | 112 (17) |
Chemotherapy protocol n (%) | |||
Protocols before 20001 | 325 (52) | − | 325 (52) |
Protocols after 20002 | 297 (48) | − | 297 (48) |
OSC protocols | − | 39 | 39 |
Anthracycline dose3 (range, mg/m2) | 60–840 | 180–360 | 60–840 |
Anthracycline dose n (%) | |||
≤ 240 mg/m2 | 457 (74) | 6 (15) | 463 (70) |
> 240 mg/m2 | 163 (26) | 33 (85) | 196 (30) |
Patients with pathological FS4 n | 18 | 2 | 20 |